Home › Breast Cancer › NCT07014618

Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

Impact of Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Subjects must have histologically or cytologically confirmed Breast or Prostate Cancer.
* Subjects must be 18 years of age or older. This study requires informed consent by the subject.
* Subjects must be of African American race, Native American race, or Hispanic ethnicity.
* Subjects scheduled to undergo RT for Cancer Treatment.
* Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Subjects NOT of African American race, Native American race or Hispanic ethnicity.
* Subjects WITHOUT histologically/cytologically confirmed Breast or Prostate Cancer.
* Subjects younger than 18 years old.

About the study

The purpose of this clinical trial is to evaluate radiation therapy (RT) completion rates among underrepresented cancer populations using qualitative measurements. Additionally, the study aims to assess the impact of patient navigators on supporting patients through their radiation care, as well as their influence on adherence to standard of care treatment modalities.

What is being tested

• Pre & Post Surveys (other)
• Opt Out of Questionnaire (other)

Sponsor: University of Oklahoma · Participants: 420 · Started: Oct 16, 2025

Contact the study team

• Lead Onco Nurse · Phone: 405-271-8777
• Shearwood McClelland III, MD · Phone: 405-271-3016

Official record on ClinicalTrials.gov — NCT07014618

Locations in the U.S.

Conditions

• Breast Cancer
• Prostate Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.